[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA30724B1 - Procede de preparation d'acide 4-amino-butyrique substitue par biaryle ou de derives de celui-ci et leur utilisation pour produire des inhibiteurs de nep. - Google Patents

Procede de preparation d'acide 4-amino-butyrique substitue par biaryle ou de derives de celui-ci et leur utilisation pour produire des inhibiteurs de nep.

Info

Publication number
MA30724B1
MA30724B1 MA31739A MA31739A MA30724B1 MA 30724 B1 MA30724 B1 MA 30724B1 MA 31739 A MA31739 A MA 31739A MA 31739 A MA31739 A MA 31739A MA 30724 B1 MA30724 B1 MA 30724B1
Authority
MA
Morocco
Prior art keywords
biaryl
derivatives
amino
substituted
producing
Prior art date
Application number
MA31739A
Other languages
English (en)
Inventor
David Hook
Bernhard Wietfeld
Matthias Lotz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37814152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30724(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30724B1 publication Critical patent/MA30724B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/30—Preparation of optical isomers
    • C07C227/32—Preparation of optical isomers by stereospecific synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22—Organic complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UN PROCÉDÉ DESTINÉ À PRODUIRE UN COMPOSÉ DE FORMULE (I) OU UN SEL DE CELUI-CI, FORMULE DANS LAQUELLE R1 ET R1´ SONT INDÉPENDAMMENT HYDROGÈNE OU UN GROUPE DE PROTECTION D'AMINE, ET R2 EST UN GROUPE CARBOXYLIQUE OU UN GROUPE ESTER. LE PROCÉDÉ CONSISTE À FAIRE RÉAGIR UN COMPOSÉ DE FORMULE (II) OU UN SEL DE CELUI-CI, FORMULE DANS LAQUELLE R1, R1´ ET R2 SONT TELS QUE DÉFINIS CI-DESSUS, AVEC DE L'HYDROGÈNE EN LA PRÉSENCE D'UN CATALYSEUR À MÉTAL DE TRANSITION ET D'UN LIGAND CHIRAL, LE MÉTAL DE TRANSITION ÉTANT CHOISI DANS LE GROUPE 7, 8 OU 9 DU TABLEAU PÉRIODIQUE DES ÉLÉMENTS. L'INVENTION CONCERNE ÉGALEMENT DES PRODUITS POUVANT ÊTRE OBTENUS PAR LEDIT PROCÉDÉ, ET LEUR UTILISATION POUR PRODUIRE DES INHIBITEURS DE NEP. L'INVENTION A ÉGALEMENT POUR OBJET L'UTILISATION DU CATALYSEUR À MÉTAL DE TRANSITION POUR PRÉPARER DES INHIBITEURS DE NEP OU DES PROMÉDICAMENTS DE CEUX-CI.
MA31739A 2006-09-13 2009-03-30 Procede de preparation d'acide 4-amino-butyrique substitue par biaryle ou de derives de celui-ci et leur utilisation pour produire des inhibiteurs de nep. MA30724B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06120576A EP1903027A1 (fr) 2006-09-13 2006-09-13 Procédé de préparation de l' acide amino-4 butyrique ou de ses derivés et leur utilisation pour la préparation des inhibiteurs NEP

Publications (1)

Publication Number Publication Date
MA30724B1 true MA30724B1 (fr) 2009-09-01

Family

ID=37814152

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31739A MA30724B1 (fr) 2006-09-13 2009-03-30 Procede de preparation d'acide 4-amino-butyrique substitue par biaryle ou de derives de celui-ci et leur utilisation pour produire des inhibiteurs de nep.

Country Status (29)

Country Link
US (2) US20090326066A1 (fr)
EP (2) EP1903027A1 (fr)
JP (1) JP5455627B2 (fr)
KR (1) KR101401118B1 (fr)
CN (1) CN101516831B (fr)
AU (1) AU2007296889B2 (fr)
BR (1) BRPI0716990A2 (fr)
CA (1) CA2662393C (fr)
CO (1) CO6190550A2 (fr)
CY (1) CY1115696T1 (fr)
DK (1) DK2066618T3 (fr)
ES (1) ES2519446T3 (fr)
GT (1) GT200900058A (fr)
HK (1) HK1131381A1 (fr)
HR (1) HRP20140984T1 (fr)
IL (1) IL196925A (fr)
MA (1) MA30724B1 (fr)
MX (1) MX2009002746A (fr)
MY (1) MY146660A (fr)
NO (1) NO341967B1 (fr)
NZ (1) NZ574665A (fr)
PL (1) PL2066618T3 (fr)
PT (1) PT2066618E (fr)
RU (1) RU2469019C2 (fr)
SG (1) SG177205A1 (fr)
SI (1) SI2066618T1 (fr)
TN (1) TN2009000077A1 (fr)
WO (1) WO2008031567A1 (fr)
ZA (1) ZA200900779B (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2121578T3 (en) 2007-01-12 2016-12-05 Novartis Ag A process for the preparation of 4-biphenyl-4-amino-2-methylpentanoic acid
PE20091364A1 (es) 2008-01-17 2009-10-13 Novartis Ag Proceso para la preparacion de inhibidores de nep
ES2523734T3 (es) 2009-05-28 2014-12-01 Novartis Ag Derivados aminopropiónicos sustituidos como inhibidores de neprilisina
AR076706A1 (es) 2009-05-28 2011-06-29 Novartis Ag Derivados aminobutiricos sustituidos como inhibidores de neprilisina
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
PL2526088T3 (pl) * 2010-01-22 2016-01-29 Novartis Ag Produkty pośrednie inhibitorów obojętnej endopeptydazy oraz sposób ich wytwarzania
AU2011295170B2 (en) * 2010-08-23 2014-12-18 Novartis Ag Process for the preparation of intermediates for the manufacture of NEP inhibitors
SI2609071T1 (sl) * 2010-08-23 2017-01-31 Novartis Ag Novi postopek za pripravo intermediatov, uporabnih za izdelavo NEP inhibitorjev
CN103080077B (zh) * 2010-08-23 2015-06-10 诺华股份有限公司 用于制造nep抑制剂的中间体的制备工艺
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
AR092278A1 (es) * 2012-08-31 2015-04-08 Novartis Ag Proceso de obtencion de derivados n-acilicos de bifenil-alanina e intermediarios relacionados
US9102635B2 (en) 2013-02-14 2015-08-11 Novartis Ag Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy
PE20151666A1 (es) 2013-02-14 2015-11-19 Novartis Ag Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep
CN104230865B (zh) * 2013-06-13 2018-01-09 上海翰森生物医药科技有限公司 联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途
JP2016528271A (ja) * 2013-08-21 2016-09-15 ディーピーエックス ホールディングス ビー．ブイ． □新規な中間体を経由するビフェニルアラニノールの合成
CN105461587A (zh) * 2014-08-27 2016-04-06 上海翰森生物医药科技有限公司 Ahu-377半钙盐晶型及其制备方法和应用
CN106458857A (zh) * 2014-08-27 2017-02-22 上海翰森生物医药科技有限公司 AHU‑377结晶型游离酸、半钙盐、α﹣苯乙胺盐及其制备方法和应用
WO2016037098A1 (fr) 2014-09-04 2016-03-10 Concert Pharmaceuticals, Inc. Sacubitril deutérisé
PT3218351T (pt) 2014-11-14 2019-09-26 Zentiva Ks Um método para a preparação, isolamento e purificação de formas farmaceuticamente aplicáveis de ahu-377
CN104557600B (zh) * 2015-01-26 2016-05-04 苏州明锐医药科技有限公司 沙库比曲的制备方法
TW201632493A (zh) 2015-02-13 2016-09-16 諾華公司 新穎方法
CN105884644B (zh) * 2015-02-15 2020-06-09 深圳信立泰药业股份有限公司 一种中性内肽酶抑制剂盐优势形态及其制备方法
CN106146351B (zh) * 2015-04-03 2020-09-11 博瑞生物医药（苏州）股份有限公司 制备联芳基取代的4-氨基-丁酸或其衍生物的方法
CN106065006B (zh) * 2015-04-22 2020-06-05 深圳信立泰药业股份有限公司 一种中性内肽酶抑制剂盐晶型及其制备方法
CN106187808A (zh) * 2015-05-08 2016-12-07 苏州鹏旭医药科技有限公司 Ahu-377的制备方法、ahu-377中间体及ahu-377中间体的制备方法
CN104860894B (zh) * 2015-06-10 2017-05-17 北京博全健医药科技有限公司 一种抗心衰药lcz696的制备方法
CN107980038B (zh) 2015-07-02 2021-04-27 诺华股份有限公司 沙库巴曲钙盐
WO2017009784A1 (fr) 2015-07-14 2017-01-19 Cadila Healthcare Limited Formes à l'état solide de sel de trisodium du complexe valsartan/sacubitril et de sacubitril
CN105061263B (zh) * 2015-08-11 2017-03-15 苏州楚凯药业有限公司 一种nep抑制剂中间体的制备方法
CN105085322B (zh) * 2015-08-15 2017-10-03 浙江永宁药业股份有限公司 Ahu‑377中间体的制备方法及其中间体和中间体的制备方法
CN105168205A (zh) * 2015-08-18 2015-12-23 泰力特医药（湖北）有限公司 一种血管紧张素ii受体和脑啡肽酶受体双重抑制剂lcz696的制备方法
WO2017033128A1 (fr) * 2015-08-25 2017-03-02 Novartis Ag Dérivés d'acide 4-aminé-butyrique substitués par le biphényle, et leur utilisation dans la synthèse d'inhibiteurs de nep
CN105152980B (zh) * 2015-09-11 2017-03-29 浙江永宁药业股份有限公司 N‑叔丁氧羰基‑（4s）‑（对苯基苯基甲基）‑4‑氨基‑（2r）‑甲基丁酸的手性制备方法
WO2017051326A1 (fr) 2015-09-23 2017-03-30 Novartis Ag Nouveaux procédés et intermédiaires utiles dans la synthèse d'inhibiteurs d'endopeptidase neutre (nep)
CN105348209B (zh) 2015-12-09 2017-12-26 浙江天宇药业股份有限公司 一种抗心衰药lcz696的制备方法
CN105523964B (zh) * 2015-12-09 2017-05-24 苏州楚凯药业有限公司 一种抗心衰药物中间体的制备方法
EP3386955B1 (fr) 2015-12-10 2020-08-05 Novartis AG Intermédiaires pour la production de sacubitril et leurs preparation
BR112018011788A2 (pt) 2015-12-11 2018-12-04 Zentiva Ks formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação
CN106977415B (zh) * 2016-01-15 2021-03-26 广东东阳光药业有限公司 一种沙库必曲的中间体及其制备方法
WO2017141193A1 (fr) * 2016-02-16 2017-08-24 Sun Pharmaceutical Industries Limited Procédé de préparation de sacubitril ou de ses sels
CN105924355B (zh) * 2016-05-11 2018-08-17 浙江宏元药业有限公司 沙库比曲中间体及沙库比曲中间体和沙库比曲的制备方法
CN109415308B (zh) 2016-07-05 2022-09-06 诺华股份有限公司 用于早期沙卡布曲中间体的新方法
WO2018033866A1 (fr) 2016-08-17 2018-02-22 Novartis Ag Nouveaux procédés et intermédiaires pour la synthèse d'inhibiteurs de nep
CN106380421B (zh) * 2016-08-26 2017-12-08 中国科学院上海有机化学研究所 沙库必曲的合成方法
EP3522886A4 (fr) 2016-10-10 2020-02-19 Laurus Labs Limited Forme amorphe stable d'un complexe de sacubitril-valsartan trisodique et ses procédés de préparation
CN106631903A (zh) * 2016-12-16 2017-05-10 重庆市碚圣医药科技股份有限公司 一种lcz‑696关键中间体的制备方法
ES2883363T3 (es) * 2016-12-23 2021-12-07 Novartis Ag Proceso nuevo para intermedios iniciales de sacubitrilo
CN107011203B (zh) * 2017-04-28 2019-03-29 江苏阿尔法药业有限公司 一种lcz696中间体ahu-377的制备方法
CN107522628A (zh) * 2017-09-20 2017-12-29 吉尔生化（上海）有限公司 一种l‑3‑（6‑乙酰基‑2‑萘胺基）‑2‑氨基丙酸的合成方法
CN108084058A (zh) * 2017-12-15 2018-05-29 江苏中邦制药有限公司 一种lcz696中间体的制备方法
CN108373423B (zh) * 2018-04-28 2020-10-23 成都苑东生物制药股份有限公司 一种沙库比曲缬沙坦复合物和/或共晶关键中间体沙库比曲钙的制备方法
CN109400504A (zh) * 2018-12-11 2019-03-01 重庆三圣实业股份有限公司 Lcz696中间体非对映异构体的分离纯化方法
CN109503404A (zh) * 2018-12-28 2019-03-22 凯瑞斯德生化(苏州)有限公司 一种lcz-696关键中间体的制备方法
CN111748590B (zh) * 2019-03-29 2024-05-28 弈柯莱(台州)药业有限公司 转氨酶在制备Sacubitril中间体中的应用
CN110128298B (zh) * 2019-06-13 2021-08-03 南京一心和医药科技有限公司 一种沙库巴曲中间体的合成方法
CN112574132B (zh) * 2019-09-30 2024-02-27 广东东阳光药业股份有限公司 一种沙库必曲缬沙坦钠的制备方法
CN113135836A (zh) * 2020-01-20 2021-07-20 鲁南制药集团股份有限公司 一种沙库巴曲钙盐的制备方法
CN113321600B (zh) * 2020-02-28 2024-06-14 四川科伦药物研究院有限公司 制备手性联芳基取代的4-氨基-丁酸及其衍生物的方法
CN113387841A (zh) * 2020-03-13 2021-09-14 凯特立斯（深圳）科技有限公司 一种沙库必曲中间体的合成方法
CN111269148B (zh) * 2020-04-08 2022-02-08 台州职业技术学院 一种沙库比曲中间体的制备方法
JP7064527B2 (ja) * 2020-05-01 2022-05-10 ノバルティス アーゲー サクビトリルカルシウム塩
CN112745246A (zh) * 2020-12-30 2021-05-04 重庆市碚圣医药科技股份有限公司 一种沙库必曲中间体的纯化方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250522A (en) * 1992-10-09 1993-10-05 Ciba-Geigy Corporation Phosphono/biaryl substituted amino acid derivatives
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
JP3020128B2 (ja) * 1994-03-08 2000-03-15 高砂香料工業株式会社 光学活性カルボン酸の製造法
US5550119A (en) * 1995-03-02 1996-08-27 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives as ECE inhibitors
US6214763B1 (en) * 1997-05-20 2001-04-10 Firmenich Sa Ruthenium catalysts and their use in the asymmetric hydrogenation of weakly coordinating substrates
ES2219493T3 (es) * 2000-01-27 2004-12-01 Warner-Lambert Company Sintesis asimetrica de la pregabalina.
GB0026890D0 (en) * 2000-11-03 2000-12-20 Ici Plc Catalyst
AR043515A1 (es) * 2003-03-19 2005-08-03 Merck & Co Inc Procedimiento para preparar derivados quirales beta aminoacidos mediante hidrogenacion asimetrica
WO2005016178A2 (fr) 2003-08-04 2005-02-24 Auragin, Inc. Implant cochleaire
EP1667957A2 (fr) * 2003-09-25 2006-06-14 Warner-Lambert Company LLC Acides amines a affinite pour la proteine a2d
US20080026933A1 (en) * 2004-07-05 2008-01-31 Benoit Pugin 1,1'-Diphosphinoferrocenes Having 2,2'-Bound Achiral Or Chiral Radicals
GB0418046D0 (en) * 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
WO2006057904A1 (fr) * 2004-11-23 2006-06-01 Merck & Co., Inc. Preparation stereoselective de 4-aryl piperidine amides par hydrogenation asymetrique d'une enamide prochirale et intermediaires de ce procede
AT501193B1 (de) * 2004-12-27 2007-03-15 Dsm Fine Chem Austria Gmbh Verfahen zur übergangsmetall - katalysierten asymmetrischen hydrierung von acrylsäurederivaten

Also Published As

Publication number Publication date
TN2009000077A1 (en) 2010-08-19
IL196925A0 (en) 2009-11-18
NO20091242L (no) 2009-03-25
US20090326066A1 (en) 2009-12-31
NZ574665A (en) 2012-03-30
JP5455627B2 (ja) 2014-03-26
SG177205A1 (en) 2012-01-30
EP1903027A1 (fr) 2008-03-26
GT200900058A (es) 2010-03-11
NO341967B1 (no) 2018-03-05
ES2519446T3 (es) 2014-11-07
CN101516831A (zh) 2009-08-26
WO2008031567A1 (fr) 2008-03-20
HK1131381A1 (en) 2010-01-22
MX2009002746A (es) 2009-03-26
KR20090076910A (ko) 2009-07-13
RU2009113666A (ru) 2010-10-20
KR101401118B1 (ko) 2014-05-29
RU2469019C2 (ru) 2012-12-10
PL2066618T3 (pl) 2015-01-30
PT2066618E (pt) 2014-09-10
SI2066618T1 (sl) 2014-11-28
JP2010503628A (ja) 2010-02-04
DK2066618T3 (da) 2014-09-22
ZA200900779B (en) 2009-12-30
US8946481B2 (en) 2015-02-03
EP2066618B1 (fr) 2014-07-23
EP2066618A1 (fr) 2009-06-10
BRPI0716990A2 (pt) 2014-02-04
AU2007296889B2 (en) 2012-03-01
CA2662393A1 (fr) 2008-03-20
WO2008031567B1 (fr) 2008-05-08
MY146660A (en) 2012-09-14
CA2662393C (fr) 2015-11-03
CO6190550A2 (es) 2010-08-19
US20130066101A1 (en) 2013-03-14
IL196925A (en) 2013-10-31
AU2007296889A1 (en) 2008-03-20
HRP20140984T1 (hr) 2014-12-05
CY1115696T1 (el) 2017-01-25
CN101516831B (zh) 2013-12-25

Similar Documents

Publication Publication Date Title
MA30724B1 (fr) Procede de preparation d'acide 4-amino-butyrique substitue par biaryle ou de derives de celui-ci et leur utilisation pour produire des inhibiteurs de nep.
MA31951B1 (fr) Nouveaux procedes
MA31284B1 (fr) Nouveau procede
MA32089B1 (fr) Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
MA29311B1 (fr) Derives d'isoxazolines et son nouveau procede de production
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MA30483B1 (fr) Utilisation de biphenylamides d'acide arylcarboxylique pour le traitement de semences.
MA29412B1 (fr) Derives d'acetylene
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
PE20040164A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas
WO2005092895A3 (fr) Composes acide propanoique beta piperidino methyle alpha aryle ou heteroaryle utilises comme antagonistes du recepteur orl1
MA33240B1 (fr) Inhibiteurs de bêta-sécrétase
TW200635509A (en) 5-Alkoxyalkyl-6-alkyl-7-aminoazolopyrimidines, process for their preparation, their use for controlling harmful fungi, and compositions comprising them
MX2009003739A (es) Derivados de hidrobenzamida como inhibidores de hsp90.
MA32642B1 (fr) Amides utiles en therapie
MA32088B1 (fr) Dérivés bicycliques de carboxamides azabicycliques, leur préparation et leur application en thérapeutique
MA37891B1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MX2013000295A (es) Procedimiento de preparacion de un inhibidor especifico de la trombina.
DE602007008389D1 (de) Synthese von phenolischen estern von hydroxymethylphenolen
MA31834B1 (fr) 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, leur procédé de production et leur utilisation comme anti-inflammatoires
SG170794A1 (en) Process for preparation of hiv protease inhibitors
IN2014DN01993A (fr)
MA31163B1 (fr) Dérivé de pyridyl-triazolopyrimidine ou son sel, pesticide la contenant et son procédé de production
MA34958B1 (fr) Nouvelle forme cristalline vii d'agomelatine ,son procedes de preparation et utilisation et composition pharmaceutique la contenant
MA29852B1 (fr) Synthese d'inhibiteurs de la renine impliquant une reaction de cycloaddition